GeNeuro enrolls first patient in temelimab Phase 2 multiple sclerosis trial in collaboration with the Karolinska Institutet’s Academic Specialist Center (ASC)

Geneva, Switzerland, June 25, 2020 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS), today announces the inclusion of the first patient in its Phase 2 trial of […]